Basilea Pharmaceutica (XSWX:BSLN) Accounts Receivable: CHF13.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
60 GF Score
Price CHF65.40
GF Value CHF57.25
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Accounts Receivable?

Basilea Pharmaceutica XSWX:BSLN -0.15% 60 Accounts Receivable is CHF13.9 Mil as of Jun. 2026. GuruFocus rates XSWX:BSLN with a GF Score™ of 60/100 and a GF Value™ of CHF57.25 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Basilea Pharmaceutica's accounts receivables for the quarter that ended in Jun. 2026 was CHF13.9 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Basilea Pharmaceutica's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 21.29.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Basilea Pharmaceutica's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was CHF4.91.

Basilea Pharmaceutica Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Basilea Pharmaceutica's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=13.879/118.996*91
=21.29

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Basilea Pharmaceutica's accounts receivable are only considered to be worth 75% of book value:

Basilea Pharmaceutica's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(173.052+0.75 * 13.879+0.5 * 26.038-135.685
-0-0)/12.377
=4.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Basilea Pharmaceutica Accounts Receivable Related Terms

Basilea Pharmaceutica Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Accounts Receivable Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.95 33.15 27.89 8.88 13.49

Basilea Pharmaceutica Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.08 8.88 16.64 13.49 13.88
XSWX:BSLN
60GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of CHF13.9 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Accounts Receivable of CHF13.9 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Accounts Receivable too high?
Basilea Pharmaceutica's current Accounts Receivable is CHF13.9 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Accounts Receivable compare to VRTX and REGN?
Basilea Pharmaceutica's Accounts Receivable of CHF13.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Accounts Receivable is CHF13.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF57.25, compared to a current price of CHF65.40 — trading 14.2% above its estimated fair value. The current Accounts Receivable is CHF13.9 Mil. Basilea Pharmaceutica's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Accounts Receivable is CHF13.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued. The current stock price of CHF65.40 is trading 14.2% above its estimated GF Value™ of CHF57.25. GuruFocus considers Basilea Pharmaceutica to be Modestly Overvalued.

Key valuation signals for XSWX:BSLN:

  • Accounts Receivable: CHF13.9 Mil
  • GF Value™: CHF57.25 vs. price of CHF65.40 (14.2% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
60GF Score

Get the complete analysis for XSWX:BSLN

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF65.40
Price
CHF57.25
GF Value